Latest & greatest articles for prednisone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prednisone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prednisone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prednisone

1. Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS.

Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS. BACKGROUND: Early initiation of antiretroviral therapy (ART) in human immunodeficiency virus (HIV)-infected patients who have tuberculosis reduces mortality among patients with low CD4 counts, but it increases the risk of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (IRIS). METHODS: We conducted this randomized, double-blind, placebo-controlled trial to assess whether prophylactic (...) prednisone can safely reduce the incidence of paradoxical tuberculosis-associated IRIS in patients at high risk for the syndrome. We enrolled HIV-infected patients who were initiating ART (and had not previously received ART), had started tuberculosis treatment within 30 days before initiating ART, and had a CD4 count of 100 cells or fewer per microliter. Patients received either prednisone (at a dose of 40 mg per day for 14 days, then 20 mg per day for 14 days) or placebo. The primary end point

NEJM2018

2. Prednisone

Prednisone Top results for prednisone - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search (...) button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for prednisone The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory

Trip Latest and Greatest2018

3. Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921

Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 29624463 2018 06 15 1527-7755 36 15 2018 May 20 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After (...) Radical Prostatectomy: SWOG S9921. 1498-1504 10.1200/JCO.2017.76.4126 Purpose Patients with high-risk prostate cancer after radical prostatectomy are at risk for death. Adjuvant androgen-deprivation therapy (ADT) may reduce this risk. We hypothesized that the addition of mitoxantrone and prednisone (MP) to adjuvant ADT could reduce mortality compared with adjuvant ADT alone. Methods Eligible patients had cT1-3N0 prostate cancer with one or more high-risk factors after radical prostatectomy (Gleason

EvidenceUpdates2018

4. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial

Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial 29326030 2018 02 07 1474-5488 19 2 2018 Feb The Lancet. Oncology Lancet Oncol. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive (...) prostate cancer (LATITUDE): an international, randomised phase 3 trial. 194-206 S1470-2045(17)30911-7 10.1016/S1470-2045(17)30911-7 In the LATITUDE trial, addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) improved overall survival compared with placebos plus ADT in patients with newly diagnosed, high-risk, metastatic castration-naive prostate cancer. Understanding the effects of treatments on patient-reported outcomes (PROs) and health-related quality of life (HRQOL

EvidenceUpdates2018

5. Dapagliflozin for prednisone-induced hyperglycaemia in acute exacerbation of chronic obstructive pulmonary disease

Dapagliflozin for prednisone-induced hyperglycaemia in acute exacerbation of chronic obstructive pulmonary disease 29316157 2018 02 07 1463-1326 2018 Jan 05 Diabetes, obesity & metabolism Diabetes Obes Metab Dapagliflozin for prednisone-induced hyperglycaemia in acute exacerbation of chronic obstructive pulmonary disease. 10.1111/dom.13209 The aim of the present study was to compare the effectiveness and safety of add-on treatment with dapagliflozin to placebo in patients with prednisone (...) in better glycaemic control compared with placebo in participants with prednisone-induced hyperglycaemia during AECOPD. © 2018 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. Gerards Maaike C MC http://orcid.org/0000-0003-1034-4141 Department of Internal Medicine, MC Slotervaart, Amsterdam, The Netherlands. Venema Gerdien E GE Department of Pulmonology, Isala, Zwolle, The Netherlands. Patberg Kornelis W KW Department of Pulmonology, Isala, Zwolle, The Netherlands. Kross

EvidenceUpdates2018

6. Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone

Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone European Medicines Agency - News and Events - Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone Search for medicines Main navigation News and press releases Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone Press release 09/03/2018 Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone Ongoing (...) clinical study shows an increased risk of death and fractures with the combination The European Medicines Agency (EMA) has recommended contraindicating the use of the prostate cancer medicine Xofigo (radium-223 dichloride) with Zytiga (abiraterone acetate) and prednisone/prednisolone, due to an increased risk of death and fractures with this combination. EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has reviewed the preliminary data from an ongoing clinical study in metastatic prostate

European Medicines Agency - EPARs2018

7. Randomized Trial of Dexamethasone Versus Prednisone for Children with Acute Asthma Exacerbations

Randomized Trial of Dexamethasone Versus Prednisone for Children with Acute Asthma Exacerbations 29173304 2017 12 11 2017 12 11 1097-6833 191 2017 Dec The Journal of pediatrics J. Pediatr. Randomized Trial of Dexamethasone Versus Prednisone for Children with Acute Asthma Exacerbations. 190-196.e1 S0022-3476(17)31090-9 10.1016/j.jpeds.2017.08.030 To determine whether 2 doses of dexamethasone is as effective as 5 days of prednisolone/prednisone therapy in improving symptoms and quality (...) of life of children with asthma exacerbations admitted to the emergency department (ED). We conducted a randomized, noninferiority trial including patients aged 1-14 years who presented to the ED with acute asthma to compare the efficacy of 2 doses of dexamethasone (0.6 mg/kg/dose, experimental treatment) vs a 5-day course of prednisolone/prednisone (1.5 mg/kg/d, followed by 1 mg/kg/d on days 2-5, conventional treatment). Two follow-up telephone interviews were completed at 7 and 15 days. The primary outcome

EvidenceUpdates2018

8. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, ph

Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, ph 29033099 2017 12 15 2017 12 15 1474-5488 18 11 2017 Nov The Lancet. Oncology Lancet Oncol. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant (...) to chemotherapy and that confers treatment resistance. We aimed to assess whether custirsen in combination with cabazitaxel and prednisone increases overall survival in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel. In this randomised, open-label, international, phase 3 trial, men with radiographically documented metastatic castration-resistant prostate cancer that had progressed after docetaxel treatment with a Karnofsky performance status of more than 70

EvidenceUpdates2018

9. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. Background The combination of bortezomib, melphalan, and prednisone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. Daratumumab has shown efficacy in combination with standard-of-care regimens in patients with relapsed or refractory multiple myeloma. Methods In this phase 3 trial, we randomly assigned 706 patients with newly (...) diagnosed multiple myeloma who were ineligible for stem-cell transplantation to receive nine cycles of bortezomib, melphalan, and prednisone either alone (control group) or with daratumumab (daratumumab group) until disease progression. The primary end point was progression-free survival. Results At a median follow-up of 16.5 months in a prespecified interim analysis, the 18-month progression-free survival rate was 71.6% (95% confidence interval [CI], 65.5 to 76.8) in the daratumumab group and 50.2% (95

NEJM2017

10. Radium-223 dichloride (Xofigo): do not use in combination with abiraterone and prednisone/prednisolone, following clinical trial signal of increased risk of death and fractures

Radium-223 dichloride (Xofigo): do not use in combination with abiraterone and prednisone/prednisolone, following clinical trial signal of increased risk of death and fractures Radium-223 dichloride (Xofigo▼): do not use in combination with abiraterone and prednisone/prednisolone, following clinical trial signal of increased risk of death and fractures - GOV.UK GOV.UK uses cookies to make the site simpler. Search Radium-223 dichloride (Xofigo▼): do not use in combination with abiraterone (...) and prednisone/prednisolone, following clinical trial signal of increased risk of death and fractures From: Published: 14 December 2017 Therapeutic area: and A European review has begun into the safety of radium-223 dichloride following an observed increase in the incidence of deaths and fractures in patients with chemotherapy-naive metastatic castration-resistant prostate cancer receiving radium-223 dichloride in combination with abiraterone acetate (Zytiga) and prednisone/prednisolone as part of a clinical

MHRA Drug Safety Update2017

11. Successful long-term treatment of paraneoplastic optic neuropathy with mycophenolate mofetil, prednisone, and plasmapheresis

Successful long-term treatment of paraneoplastic optic neuropathy with mycophenolate mofetil, prednisone, and plasmapheresis 29260113 2018 11 13 2451-9936 8 2017 Dec American journal of ophthalmology case reports Am J Ophthalmol Case Rep Successful long-term treatment of paraneoplastic optic neuropathy with mycophenolate mofetil, prednisone, and plasmapheresis. 31-34 10.1016/j.ajoc.2017.09.003 To report long-term follow-up of a case of paraneoplastic optic neuropathy (PON) successfully treated (...) with combination therapy. We present a confirmed case of PON from cutaneous melanoma with nearly six years of meticulous follow-up in which vision was preserved and disease remission was successfully induced with combination mycophenolate mofetil, prednisone, and plasmapheresis therapy. Treatment of PON and long-term follow-up are not well described in the literature. In our case of PON, vision was preserved and disease remission was achieved with mycophenolate mofetil, prednisone, and plasmapheresis

American journal of ophthalmology case reports2017 Full Text: Link to full Text with Trip Pro

12. Levocetirizine and Prednisone Are Not Superior to Levocetirizine Alone for the Treatment of Acute Urticaria: A Randomized Double-Blind Clinical Trial

Levocetirizine and Prednisone Are Not Superior to Levocetirizine Alone for the Treatment of Acute Urticaria: A Randomized Double-Blind Clinical Trial 28476259 2017 05 06 2017 05 06 1097-6760 2017 May 02 Annals of emergency medicine Ann Emerg Med Levocetirizine and Prednisone Are Not Superior to Levocetirizine Alone for the Treatment of Acute Urticaria: A Randomized Double-Blind Clinical Trial. S0196-0644(17)30264-0 10.1016/j.annemergmed.2017.03.006 We evaluate the efficacy of a 4-day course (...) of prednisone added to antihistamine for the management of acute urticaria in an emergency department (ED). In this double-blind randomized clinical trial, patients were eligible for inclusion if aged 18 years or older and with acute urticaria of no more than 24 hours' duration. Patients with anaphylaxis or who had received antihistamines or glucocorticoids during the previous 5 days were not included. In addition to levocetirizine (5 mg orally for 5 days), patients were assigned to receive prednisone (40

EvidenceUpdates2017

13. Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial

Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial 28283282 2017 03 11 2017 06 08 2017 06 08 1474-5488 18 4 2017 Apr The Lancet. Oncology Lancet Oncol. Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. 473-485 S1470 (...) -2045(17)30168-7 10.1016/S1470-2045(17)30168-7 Clusterin is a chaperone protein associated with treatment resistance and upregulated by apoptotic stressors such as chemotherapy. Custirsen is a second-generation antisense oligonucleotide that inhibits clusterin production. The aim of the SYNERGY trial was to investigate the effect of custirsen in combination with docetaxel and prednisone on overall survival in patients with metastatic castration-resistant prostate cancer. SYNERGY was a phase 3

EvidenceUpdates2017

14. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone 28426350 2017 04 20 2017 04 20 1527-7755 2017 Apr 20 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated (...) With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. JCO2017726984 10.1200/JCO.2017.72.6984 Purpose The standard treatment of patients with diffuse large B-cell lymphoma (DLBCL) is rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Lenalidomide, an immunomodulatory agent, has shown activity in DLBCL. This randomized phase III trial compared lenalidomide as maintenance therapy with placebo in elderly patients with DLBCL

EvidenceUpdates2017

15. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. Background Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus prednisone is indicated for metastatic castration-resistant prostate cancer. We evaluated the clinical benefit of abiraterone acetate plus prednisone with androgen-deprivation therapy in patients with newly diagnosed, metastatic, castration-sensitive prostate cancer. Methods In this double-blind, placebo-controlled, phase 3 trial (...) , we randomly assigned 1199 patients to receive either androgen-deprivation therapy plus abiraterone acetate (1000 mg daily, given once daily as four 250-mg tablets) plus prednisone (5 mg daily) (the abiraterone group) or androgen-deprivation therapy plus dual placebos (the placebo group). The two primary end points were overall survival and radiographic progression-free survival. Results After a median follow-up of 30.4 months at a planned interim analysis (after 406 patients had died), the median

NEJM2017

16. Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second Computer-Assisted Management in Early Rheumatoid Arthritis trial

Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second Computer-Assisted Management in Early Rheumatoid Arthritis trial 28450312 2017 04 28 2017 06 01 1468-2060 2017 Apr 27 Annals of the rheumatic diseases Ann. Rheum. Dis. Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second Computer-Assisted Management in Early Rheumatoid (...) Arthritis trial. annrheumdis-2016-210647 10.1136/annrheumdis-2016-210647 In the second Computer-Assisted Management in Early Rheumatoid Arthritis trial, patients had started with methotrexate and 10 mg prednisone (MTX+pred) or placebo (MTX+plac). After the trial, prednisone was tapered and stopped, if possible. The objective was to compare, during the post-trial follow-up between the two former strategy groups, initiation of the first biological disease-modifying antirheumatic drug (bDMARD

EvidenceUpdates2017

17. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. BACKGROUND: High doses of corticosteroids are considered the standard treatment for pemphigus. Because long-term corticosteroid treatment can cause severe and even life-threatening side-effects in patients with this disease, we assessed whether first-line use of rituximab as adjuvant therapy could (...) participants (1:1) to receive either oral prednisone alone, 1·0 or 1·5 mg/kg per day tapered over 12 or 18 months (prednisone alone group), or 1000 mg of intravenous rituximab on days 0 and 14, and 500 mg at months 12 and 18, combined with a short-term prednisone regimen, 0·5 or 1·0 mg/kg per day tapered over 3 or 6 months (rituximab plus short-term prednisone group). Follow-up was for 3 years (study visits were scheduled weekly during the first month of the study, then monthly until month 24

Lancet2017

18. Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia

Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia 27471201 2016 07 29 2016 10 03 1399-3003 48 4 2016 Oct The European respiratory journal Eur. Respir. J. Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia. 1150-1159 10.1183/13993003.00474-2016 In a double-blind, randomised, placebo-controlled trial of hospitalised patients with community-acquired pneumonia (CAP), we demonstrated shorter time to clinical stability (TTCS (...) ) with adjunct corticosteroid therapy compared with placebo.We did a pre-planned, exploratory analysis of any association between microbiological diagnosis, antibiotic treatment and procalcitonin level and effect of prednisone on TTCS, mortality, and CAP complications (n=726 participants, enrolled between December 2009 and May 2014). Multiplex viral real time PCR was systematically performed in nasopharyngeal swabs beginning November 2011 (n=489). Other investigations and treatments were at the discretion

EvidenceUpdates2016

19. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy

Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy 27566742 2016 08 27 2017 05 12 2017 05 12 1526-632X 87 20 2016 Nov 15 Neurology Neurology Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. 2123-2131 To assess safety and efficacy of deflazacort (DFZ) and prednisone (PRED) vs placebo in Duchenne muscular dystrophy (DMD). This phase III, double-blind, randomized, placebo-controlled, multicenter study evaluated (...) Justine (M.V.), Montreal, Canada; and Marathon Pharmaceuticals, LLC (J.S.D., J.M.M.), Northbrook, IL. eng Clinical Trial, Phase III Comparative Study Journal Article Multicenter Study Randomized Controlled Trial 2016 08 26 United States Neurology 0401060 0028-3878 0 Anti-Inflammatory Agents 0 Pregnenediones KR5YZ6AE4B deflazacort VB0R961HZT Prednisone AIM IM Lancet Neurol. 2010 Feb;9(2):177-89 19945914 Neuromuscul Disord. 1991;1(4):261-6 1822804 J Clin Neuromuscul Dis. 2001 Jun;2(4):179-83 19078632

EvidenceUpdates2016

20. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000

Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000 26888258 2016 04 29 2017 02 03 1528-0020 127 17 2016 Apr 28 Blood Blood Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. 2101-12 10.1182/blood-2015-09-670729 Induction therapy for childhood acute lymphoblastic leukemia (ALL) traditionally includes prednisone; yet, dexamethasone may have higher antileukemic (...) potency, leading to fewer relapses and improved survival. After a 7-day prednisone prephase, 3720 patients enrolled on trial Associazione Italiana di Ematologia e Oncologia Pediatrica and Berlin-Frankfurt-Münster (AIEOP-BFM) ALL 2000 were randomly selected to receive either dexamethasone (10 mg/m(2) per day) or prednisone (60 mg/m(2) per day) for 3 weeks plus tapering in induction. The 5-year cumulative incidence of relapse (± standard error) was 10.8 ± 0.7% in the dexamethasone and 15.6 ± 0.8

EvidenceUpdates2016